Enliven Therapeutics, Inc. (NASDAQ:ELVN) CEO Samuel Kintz Sells 16,710 Shares

Enliven Therapeutics, Inc. (NASDAQ:ELVNGet Free Report) CEO Samuel Kintz sold 16,710 shares of the stock in a transaction dated Wednesday, October 9th. The stock was sold at an average price of $28.15, for a total transaction of $470,386.50. Following the transaction, the chief executive officer now directly owns 1,003,816 shares of the company’s stock, valued at approximately $28,257,420.40. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Samuel Kintz also recently made the following trade(s):

  • On Monday, October 7th, Samuel Kintz sold 2,730 shares of Enliven Therapeutics stock. The stock was sold at an average price of $27.50, for a total transaction of $75,075.00.
  • On Friday, October 4th, Samuel Kintz sold 12,206 shares of Enliven Therapeutics stock. The shares were sold at an average price of $27.51, for a total transaction of $335,787.06.
  • On Tuesday, October 1st, Samuel Kintz sold 526 shares of Enliven Therapeutics stock. The stock was sold at an average price of $27.54, for a total value of $14,486.04.
  • On Monday, August 26th, Samuel Kintz sold 12,000 shares of Enliven Therapeutics stock. The shares were sold at an average price of $22.89, for a total value of $274,680.00.
  • On Wednesday, July 31st, Samuel Kintz sold 2,270 shares of Enliven Therapeutics stock. The shares were sold at an average price of $27.56, for a total value of $62,561.20.
  • On Thursday, July 25th, Samuel Kintz sold 12,000 shares of Enliven Therapeutics stock. The stock was sold at an average price of $24.92, for a total transaction of $299,040.00.

Enliven Therapeutics Trading Down 4.4 %

Shares of ELVN opened at $26.97 on Friday. Enliven Therapeutics, Inc. has a 1 year low of $9.80 and a 1 year high of $28.62. The stock has a 50-day simple moving average of $23.34 and a 200-day simple moving average of $22.22.

Enliven Therapeutics (NASDAQ:ELVNGet Free Report) last issued its quarterly earnings results on Tuesday, August 13th. The company reported ($0.41) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.58) by $0.17. As a group, equities analysts predict that Enliven Therapeutics, Inc. will post -1.98 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in ELVN. Quest Partners LLC lifted its stake in Enliven Therapeutics by 87.3% in the second quarter. Quest Partners LLC now owns 1,592 shares of the company’s stock worth $37,000 after acquiring an additional 742 shares during the last quarter. China Universal Asset Management Co. Ltd. lifted its stake in Enliven Therapeutics by 67.0% in the first quarter. China Universal Asset Management Co. Ltd. now owns 7,952 shares of the company’s stock worth $140,000 after acquiring an additional 3,189 shares during the last quarter. EntryPoint Capital LLC purchased a new position in Enliven Therapeutics in the first quarter worth approximately $167,000. SG Americas Securities LLC purchased a new position in Enliven Therapeutics in the third quarter worth approximately $256,000. Finally, The Manufacturers Life Insurance Company purchased a new position in Enliven Therapeutics in the second quarter worth approximately $322,000. Hedge funds and other institutional investors own 95.08% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, HC Wainwright restated a “buy” rating and issued a $37.00 price objective on shares of Enliven Therapeutics in a report on Tuesday, October 1st.

Check Out Our Latest Research Report on ELVN

About Enliven Therapeutics

(Get Free Report)

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.

Read More

Insider Buying and Selling by Quarter for Enliven Therapeutics (NASDAQ:ELVN)

Receive News & Ratings for Enliven Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enliven Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.